Atara Biotherape Stock Price, News & Analysis

Eikon Therapeutics has appointed Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer, effective July 11, 2022. Dr. Baynes, a distinguished oncologist with extensive experience, previously held senior roles at Merck and Amgen, contributing to the development of significant drugs like Keytruda. He will lead the company's clinical research and development, leveraging Eikon's advanced technologies in drug discovery. This appointment aims to strengthen Eikon's ability to deliver innovative therapies for serious illnesses.

Atara Biotherapeutics (NASDAQ: ATRA) will host an EBV and MS Day on March 22, 2022, from 4:00 p.m. EDT. CEO Dr. Pascal Touchon and the management team will discuss the role of Epstein-Barr virus (EBV) in multiple sclerosis (MS), the development of ATA188, and review Phase 1 clinical data. Renowned experts like Mark Freedman and Lawrence Steinman will provide insights. The event includes a conference call for analysts and investors, with a live webcast available on atarabio.com.

Atara Biotherapeutics (NASDAQ: ATRA) reported granting 45,040 restricted stock units and 39,978 stock options to newly hired employees. These awards were approved by Atara’s Compensation Committee and are part of the 2018 Inducement Plan. The restricted stock units will vest over four years, with 25% vesting on the first anniversary. The stock options have a ten-year term and an exercise price of $10.21 per share. This announcement aligns with Nasdaq Listing Rule 5635(c)(4) requirements.

Atara Biotherapeutics (NASDAQ: ATRA) will have its CEO, Pascal Touchon, participate in a cell therapy panel at the Cowen 42nd Annual Virtual Healthcare Conference on March 9, 2022, at 9:10 a.m. EST. The event emphasizes Atara's leadership in T-cell immunotherapy, particularly leveraging its allogeneic Epstein-Barr virus (EBV) platform for cancer and autoimmune disease treatments. A live webcast will be available on their website, with an archived replay accessible for 30 days post-presentation.

Atara Biotherapeutics (Nasdaq: ATRA) announced that a U.S. BLA submission for tab-cel is not expected in Q2 2022 due to further FDA alignment needed. However, the EU approval is on track for Q4 2022. The company reported a Q4 2021 net loss of $93.3 million and a total operating expense increase of 18% compared to the previous year. Significant advances were made in the development of ATA188 for progressive multiple sclerosis, which has received Fast Track designation from the FDA. Atara also entered a $100 million strategic manufacturing partnership with Fujifilm.

Atara Biotherapeutics (NASDAQ: ATRA) reported a serious adverse event (SAE) related to its autologous mesothelin CAR T therapy, ATA2271, during a Phase 1 study at Memorial Sloan Kettering Cancer Center (MSK). Following this event, MSK temporarily paused patient enrollment in the trial. The SAE involved a patient with prior malignancies and is currently under evaluation. Despite this setback, ongoing IND-enabling work for another CAR-T therapy, ATA3271, is unaffected. Atara emphasizes patient safety and intends to update stakeholders soon.

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) will release its fourth quarter and full year 2021 financial results on February 28, 2022. The announcement will be followed by a live conference call at 4:30 p.m. EST to discuss these results and provide a corporate update. Atara aims to deliver T-cell immunotherapy treatments for serious diseases using its unique Epstein-Barr virus T-cell platform, currently advancing several therapies, including tab-cel® for EBV-driven conditions, and ATA188 targeting multiple sclerosis.

Atara Biotherapeutics (Nasdaq: ATRA) announced the grant of 31,730 restricted stock units and stock options for 30,819 shares to new employees under its 2018 Inducement Plan, as per Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years, with 25% vesting after the first anniversary, while stock options also vest over four years with an exercise price of $15.47. This strategy aims to attract talent in T-cell immunotherapy to further develop treatments for cancer and autoimmune diseases.

Atara Biotherapeutics (NASDAQ: ATRA) has announced an agreement to sell its T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California, to FUJIFILM Diosynth Biotechnologies for USD 100 million. This strategic deal, which includes a long-term supply agreement, aims to reduce Atara's operating expenses and is expected to fund its operations into Q4 2023. Atara will retain its manufacturing expertise while FDB will expand the site to produce a wider range of allogeneic cell therapies. The deal is anticipated to close in April 2022, pending regulatory approval.